Literature DB >> 28884753

Cladribine - an old newcomer for pulsed immune reconstitution in MS.

Heinz Wiendl1.   

Abstract

The EMA has approved cladribine tablets for the treatment of multiple sclerosis. The drug is not new, and the journey to its approval has been a long one, but the old concepts that cladribine therapy are based on provide a new option for the possibility of drug-free remission.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28884753     DOI： 10.1038/nrneurol.2017.119

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  13 in total

1.  2-Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles.

Authors:  Claudio Zambaldo; Ekaterina V Vinogradova; Xiaotian Qi; Jonathan Iaconelli; Radu M Suciu; Minseob Koh; Kristine Senkane; Stormi R Chadwick; Brittany B Sanchez; Jason S Chen; Arnab K Chatterjee; Peng Liu; Peter G Schultz; Benjamin F Cravatt; Michael J Bollong
Journal:  J Am Chem Soc       Date:  2020-04-29       Impact factor: 15.419

Review 2.  Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Authors:  Jan D Lünemann; Heinz Wiendl; Tobias Ruck; Paolo A Muraro; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2019-10-24       Impact factor: 42.937

3.  Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

Authors:  Zhifeng Mao; César Álvarez-Gonzalez; Stefania De Trane; Ozlem Yildiz; Christo Albor; Gabriel Doctor; Derek Soon; George Pepper; Benjamin P Turner; Monica Marta; Joela Mathews; Gavin Giovannoni; David Baker; Klaus Schmierer
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-06-26

4.  Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers.

Authors:  Olaf Stuve; Per Soelberg Soerensen; Thomas Leist; Gavin Giovannoni; Yann Hyvert; Doris Damian; Fernando Dangond; Ursula Boschert
Journal:  Ther Adv Neurol Disord       Date:  2019-06-18       Impact factor: 6.570

Review 5.  The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.

Authors:  Robert Hermann; Mats O Karlsson; Ana M Novakovic; Nadia Terranova; Markus Fluck; Alain Munafo
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

Review 6.  Navigating choice in multiple sclerosis management.

Authors:  Ralf A Linker; Andrew Chan
Journal:  Neurol Res Pract       Date:  2019-02-28

7.  Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.

Authors:  Bryan Ceronie; Benjamin M Jacobs; David Baker; Nicolas Dubuisson; Zhifeng Mao; Francesca Ammoscato; Helen Lock; Hilary J Longhurst; Gavin Giovannoni; Klaus Schmierer
Journal:  J Neurol       Date:  2018-03-17       Impact factor: 4.849

Review 8.  Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.

Authors:  Catharina Korsukewitz; Stephen W Reddel; Amit Bar-Or; Heinz Wiendl
Journal:  Nat Rev Neurol       Date:  2020-07-08       Impact factor: 44.711

9.  Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?

Authors:  João J Cerqueira; D Alastair S Compston; Ruth Geraldes; Mario M Rosa; Klaus Schmierer; Alan Thompson; Michela Tinelli; Jacqueline Palace
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-04-04       Impact factor: 10.154

10.  Cladribine repurposed in multiple sclerosis: making a fortune out of a generic drug.

Authors:  Hans J C Buiter; Luc Derijks; Chris J J Mulder
Journal:  Eur J Hosp Pharm       Date:  2019-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.